Q-omics provides the consensus-scored ACADSB profile across patient tissues and cancer cell-line models. ACADSB expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ACADSB is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, ACADSB protein abundance shows 22,778 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KIRP, and GBM as cancer lineages where ACADSB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACADSB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACADSB survival associations across molecular data types. ACADSB RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACADSB RNA expression–survival associations across cancer types. High ACADSB expression shows unfavorable associations in UVM, but favorable associations in KIRC, BRCA, LGG, MESO and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ACADSB RNA expression.
This table summarizes ACADSB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ACADSB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACADSB shows lower tumor expression in KIRP, KIRC, THCA, COAD, KICH and LUAD. The KIRP box plot shows higher ACADSB RNA expression in normal versus tumor tissue (log2 FC = −2.121, t-test p < 0.001).
This table shows molecular features associated with ACADSB in patient tissues and cancer cell lines. In patient samples, ACADSB shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ACADSB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
